Literature DB >> 19555923

Salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in patients with burning mouth syndrome.

Kyung-Im Suh1, Young-Ku Kim, Hong-Seop Kho.   

Abstract

OBJECTIVE: To compare salivary IL-1beta, IL-6, IL-8, and TNF-alpha levels between patients with burning mouth syndrome (BMS) and controls.
DESIGN: Forty female patients with BMS (mean age: 61.6+/-10.1 years) and 20 female control subjects (mean age: 65.1+/-9.0 years) were included in the study. Unstimulated (UWS) and stimulated whole saliva samples (SWS) were collected and their flow rates were determined. Salivary IL-1beta, IL-6, IL-8, and TNF-alpha levels and total protein concentration were also determined. Salivary transferrin level was determined to investigate the level of blood contamination in saliva samples. Gingival index of the subjects was also examined. Student's t-test, Pearson's correlation analysis, and analysis of covariance were used.
RESULTS: No significant differences were found in the salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in BMS patients compared with controls. Salivary flow rates and their total protein concentrations did not differ significantly between the groups. The levels of salivary cytokines and total protein concentration correlated significantly with the level of blood contamination in both UWS and SWS.
CONCLUSION: There were no differences in the salivary levels of IL-1beta, IL-6, IL-8, and TNF-alpha in BMS patients compared with controls. Cytokine levels in whole saliva were affected mainly by the amount of blood contamination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19555923     DOI: 10.1016/j.archoralbio.2009.05.007

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  9 in total

1.  Burning Mouth Syndrome.

Authors:  Tara Renton
Journal:  Rev Pain       Date:  2011-12

Review 2.  Saliva as a diagnostic fluid.

Authors:  Daniel Malamud
Journal:  Dent Clin North Am       Date:  2011-01

3.  Translational and clinical applications of salivary diagnostics.

Authors:  W V Giannobile; J T McDevitt; R S Niedbala; D Malamud
Journal:  Adv Dent Res       Date:  2011-10

Review 4.  Is it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms.

Authors:  Hawra Aljanobi; Amarpreet Sabharwal; Bralavan Krishnakumar; Jill M Kramer
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2017-01-24

5.  Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trial.

Authors:  Natália Guimarães Barbosa; Amanda Katarinny Goes Gonzaga; Luzia Leiros de Sena Fernandes; Aldilane Gonçalves da Fonseca; Salomão Israel Monteiro Lourenço Queiroz; Telma Maria Araújo Moura Lemos; Éricka Janine Dantas da Silveira; Ana Miryam Costa de Medeiros
Journal:  Lasers Med Sci       Date:  2018-03-03       Impact factor: 3.161

6.  Salivary cytokines as a minimally-invasive measure of immune functioning in young children: correlates of individual differences and sensitivity to laboratory stress.

Authors:  Jenna L Riis; Douglas A Granger; Janet A DiPietro; Karen Bandeen-Roche; Sara B Johnson
Journal:  Dev Psychobiol       Date:  2015-01-21       Impact factor: 3.038

7.  Clinical factors affecting salivary transferrin level, a marker of blood contamination in salivary analysis.

Authors:  Jeong-Hyun Kang; Yeon-Hee Lee; Hong-Seop Kho
Journal:  BMC Oral Health       Date:  2018-03-21       Impact factor: 2.757

8.  Modulation of salivary cytokines in response to alcohol, tobacco and caffeine consumption: a pilot study.

Authors:  Chirag C Sheth; Rosa M López-Pedrajas; Maria Del Mar Jovani-Sancho; Raquel González-Martínez; Veronica Veses
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

9.  Lack of Association of Tumor Necrosis Factor-α G-308A and Transforming Growth Factor-β1 C-509T Polymorphisms in Patients with Deep Neck Space Infections.

Authors:  T Jevtović-Stoimenov; M Despotović; Z Pešić; A Cosić
Journal:  Balkan J Med Genet       Date:  2013-12       Impact factor: 0.519

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.